CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing

The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant ...
Labroots

Break the ceiling: Elevate your oncology NGS testing with expert-curated data

When the Precision Medicine Initiative was launched in 2015, it completely transformed patient care in oncology. Now, individual differences in genetics, environment and lifestyle, along with the ...
The American Journal of Managed Care

Dr Jennifer Gass Provides an Overview of FCS' Next-Generation Sequencing Laboratory

Jennifer Gass, PhD, FACMG, associate director, Genetics Laboratory, Florida Cancer Specialists & Research Institute, discusses the recent Genetics Laboratory, which focuses on next-generation ...
Business Wire

Thermo Fisher’s NGS Assay Receives FDA Approval as a Companion Diagnostic for ZEGFROVY and for Tumor Profiling

Oncomine Dx Express Test on the Ion Torrent Genexus Dx Integrated Sequencer generates results in as little as 24 hours to support timely therapy decisions A patient’s tumor profile has the potential ...
Labroots

Beyond the noise: Identifying clinically relevant mutations in somatic NGS testing

Next-generation sequencing (NGS) allows the simultaneous analysis of multiple genomic alterations with therapeutic implications, paving the way for precision medicine and transforming cancer care.
ascopubs.org

Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations

NF1-Driven Rhabdomyosarcoma Phenotypes: A Comparative Clinical and Molecular Study of NF1-Mutant Rhabdomyosarcoma and NF1-Associated Malignant Triton Tumor The Prostate Cancer Precision Medicine Multi ...